newsfilter
← Latest News
GlobeNewswire·

Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer's Trial

First Patient Expected to be Dosed Next Week with Intranasal ForalumabPET Scan Shows Presence of Untreated Neuroinflammation in Alzheimer's Patient on Leqembi® (Lecanemab) Anti-Amyloid Therapy BOSTON, Dec. 12,